An observational study in Stargardt Disease, Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy, sponsored by Astellas Pharma Global Development, Inc.. Recruiting at 15 sites in United States. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Stargardt Disease with a site in United States — 16 open to participants now, 25 under way, 3 of them phase 3. Stargardt Disease · United States.
Among the 42 studies in Stargardt Disease with a site in United States, this one is the 5th largest by planned enrollment of the 16 observational ones that give a count, is one of 6 that started in 2026, is one of 16 observational ones, reaches primary completion later than 13 of the 24 other live ones, and was the 37th registered.
68 studies on the registry are indexed under Stargardt Disease; 27 are open to participants now.
Browse Stargardt Disease studies →16 of the 42 studies in Stargardt Disease with a site in United States are open now. Recruiting first, the newest first:
Astellas Institute for Regenerative Medicine · Sites in United States
Ages 6+
Alkeus Pharmaceuticals, Inc. · Sites in United States
Ages 8–45
Cellio Therapeutics Inc · Sites in United States
Ages 18+
Ray Therapeutics, Inc. · Sites in United States
Ages 18+
Ray Therapeutics, Inc. · Sites in United States
Ages 16+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 Stargardt Disease studies recruiting now, 15 (63%) set no upper age limit and 7 (29%) stop at 75 or younger; 13 take children under 18; 6 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 16 · Phase 3 5
First in 2003; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 50 across 25 observational studies indexed under Stargardt Disease.
Median enrollment 41 across the 26 interventional studies, 63 across the 16 observational. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 42 have an industry lead sponsor. The 10 most frequent:
This study is registered under Astellas Pharma Global Development, Inc., one of the names counted as Astellas Pharma Inc. Under that name alone:
Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.
Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.
Astellas Pharma Inc has 7 studies filed under Stargardt Disease — fewer than ten, so there is no comparison to draw.
6 of the studies in Stargardt Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06435000Splice BioAn Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene | 2026-12 |
| NCT07502664Ray Therapeutics, Inc.Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD) | 2027-02 |
| NCT06048185Nanoscope Therapeutics Inc.Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study | 2027-05 |
| NCT06591806AAVantgarde Bio SrlAn Observational Study in Children and Adults With Stargardt Disease | 2027-06-30 |
| NCT03011541MD Stem CellsStem Cell Ophthalmology Treatment Study II | 2027-07-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 42 studies in Stargardt Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye. In people with macular dystrophies, some of the cells in the macula gradually stop working and may die over time. This leads to vision loss in the center of the eye. Side vision (peripheral vision) is mostly unaffected. Stargardt disease (STGD) is a type of macular dystrophy which is caused by 1 faulty gene (ABCA4). Vision loss most typically happens in childhood, but many people do not develop it until they are adults. As well as STGD, there are other macular dystrophies that look very similar to STGD but that are caused by many other different genes. Together, STGD and STGD-like conditions can be called STGD-type macular dystrophies. This is because they look the same clinically and have similar symptoms. Since different genes can cause these conditions, genetic testing is the only way to be sure which specific condition a person has.
In this study, researchers want to learn if the disease progresses in a similar way in people with STGD and STGD-like macular dystrophies. People taking part in the study will continue to manage their condition, as agreed with their own doctor. People will visit their clinic every 6 months to have various standard eye tests and imaging. The information collected will include questions about people's wellbeing, general health, medication and supplements taken, and daily activities.
Children over 6 years old and adults with STGD-type macular dystrophies may take part in this study. They will be in the study for up to 24 months (2 years). The study sponsor (Astellas) will not decide how people's condition is managed. However, the sponsor will provide instructions on when people visit their clinic and what is recorded during the study. If available, medical records, clinical and imaging data from previous visits going back 24 months will also be reviewed.
Participants aged ≥ 6 years at baseline with clinically confirmed macular dystrophy of STGD-type clinical presentation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant has a documented clinical diagnosis of macular dystrophy expressing a STGD-type clinical presentation and molecular confirmation, defined as either:
Participant has a BCVA ranging from 20/500 to 20/40 (equivalent to 15 to 70 ETDRS letters read at 1 meter)
Participant has evidence of at least questionably decreased autofluorescence (QDAF) (incomplete retinal pigment epithelial and outer retinal atrophy [iRORA]), defined as mottled or speckled hypo-autofluorescence (AF) signal, mixed with or without hyper- AF, on FAF imaging. Note: At study onset, having patches of definitely decreased autofluorescence (DDAF) within the FAF image and/or patches of complete retinal pigment epithelial and outer retinal atrophy (cRORA) on SD-OCT ≥ 250 µm will not be a requirement for participation but will be acceptable for inclusion, so long as:
Exclusion Criteria:
Participant is receiving concomitant treatment with any ocular or systemic medication known to be toxic to the lens, retina or optic nerve.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with STGD or STGD-like macular dystrophies.
Other: No Intervention
No investigational drug will be administered to participants in this study.
Change from baseline in best corrected visual acuity (BCVA) at month 12
BCVA will be measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letters chart.
Time frame: Baseline and Month 12
Change from baseline in BCVA
BCVA will be measured by ETDRS letters chart.
Time frame: Baseline and Months 6, 18 and 24/Early Termination (ET)
Change from baseline in low luminance visual acuity (LLVA)
LLVA will be measured by ETDRS letters chart.
Time frame: Baseline and Months 6, 12, 18 and 24/ET
Change from baseline in Minnesota Reading Acuity Chart (MNREAD)
MNREAD evaluates reading acuity, critical print size and maximum reading speed.
Time frame: Baseline and Months 6, 12, 18 and 24/ET
Change from baseline in mesopic MP sensitivity
Defect-mapping, fundus-controlled microperimetry (MP) will be used to assess change in mesopic MP sensitivity.
Time frame: Baseline and Months 6, 12, 18 and 24/ET
Difference between eyes in change from baseline in BCVA
BCVA will be measured by ETDRS letters chart.
Time frame: Baseline and Months 6, 12, 18 and 24/ET
Difference between eyes in change from baseline in LLVA
LLVA will be measured by ETDRS letters chart.
Time frame: Baseline and Months 6, 12, 18 and 24/ET
Change from baseline in central retinal thickness (CRT)
CRT will be measured by spectral-domain optical coherence tomography (SD-OCT).
Time frame: Baseline and Months 6, 12, 18 and 24/ET
Change from baseline in total photoreceptor thickness (TPT)
TPT will be measured by SD-OCT.
Time frame: Baseline and Months 6, 12, 18 and 24/ET
Change from baseline in ellipsoid zone (EZ) integrity
EZ integrity will be measured by SD-OCT.
Time frame: Baseline and Months 6, 12, 18 and 24/ET
Change from baseline in QDAF (Questionably Diminished Auto-Fluorescence)
QDAF will be measured with Fundus Auto-Fluorescence (FAF).
Time frame: Baseline and Months 6, 12, 18 and 24/ET
Change from baseline in DDAF (Definitely Diminished Auto-Fluorescence)
DDAF will be measured with FAF.
Time frame: Baseline and Months 6, 12, 18 and 24/ET
Difference between eyes in change from baseline in EZ integrity
EZ integrity will be measured by SD-OCT.
Time frame: Baseline and Months 6, 12, 18 and 24/ET
Difference between eyes in change from baseline in CRT
CRT will be measured by SD-OCT.
Time frame: Baseline and Months 6, 12, 18 and 24/ET
Difference between eyes in change from baseline in TPT
TPT will be measured by SD-OCT.
Time frame: Baseline and Months 6, 12, 18 and 24/ET
Difference between eyes in change from baseline in QDAF
QDAF will be measured by FAF.
Time frame: Baseline and Months 6, 12, 18 and 24/ET
Difference between eyes in change from baseline in DDAF
DDAF will be measured by FAF.
Time frame: Baseline and Months 6, 12, 18 and 24/ET
Correlation between change from baseline in structural outcomes and functional outcomes
Structural outcomes include: CRT, TPT, EZ integrity and FAF. Functional outcomes include: BCVA, LLVA, MNREAD parameters and mesopic MP sensitivity.
Time frame: Baseline and Months 6, 12, 18 and 24/ET
Longitudinal Association Between the Rate of Change in Structural and Functional Retinal Outcomes Assessed by Joint Modelling Analysis
Change from baseline in structural outcomes (CRT, TPT, EZ Integrity) and functional outcomes (BCVA, Mesopic MP sensitivity) will be used for joint modelling analysis.
Time frame: Baseline and Months 6, 12, 18 and 24/ET
Rate of Disease Progression Over Time Associated with Structural and Functional Characteristics at Baseline
Baseline characteristics: Genotype (ABCA4 vs non-ABCA4), BCVA, presence and size of central EZ, CRT and TPT, mesopic MP sensitivity. Rate of disease progression over time: Change from baseline in BCVA, EZ area, CRT, TPT, FAF and MP sensitivity.
Time frame: Baseline and Months 6, 12, 18 and 24/ET
Intraclass correlation coefficient at baseline (2 repeated measurements) in BCVA
BCVA will be measured by ETDRS letters chart.
Time frame: Baseline
Intraclass correlation coefficient longitudinally between baseline and Month 12 in BCVA
BCVA will be measured by ETDRS letters chart.
Time frame: Baseline and Month 12
Intraclass correlation coefficient at baseline (2 repeated measurements) in LLVA
LLVA will be measured by ETDRS letters chart.
Time frame: Baseline
Intraclass correlation coefficient longitudinally between baseline and Month 12 in LLVA
LLVA will be measured by ETDRS letters chart.
Time frame: Baseline and Month 12
Intraclass correlation coefficient at baseline (2 repeated measurements) in MNREAD parameters
MNREAD evaluates reading acuity, critical print size and maximum reading speed.
Time frame: Baseline
Intraclass correlation coefficient longitudinally between baseline and Month 12 in MNREAD parameters
MNREAD evaluates reading acuity, critical print size and maximum reading speed.
Time frame: Baseline and Month 12
Intraclass correlation coefficient at baseline (2 repeated measurements) in mesopic MP sensitivity
MP will be used to assess mesopic sensitivity.
Time frame: Baseline
Intraclass correlation coefficient longitudinally between baseline and Month 12 in mesopic MP sensitivity
MP will be used to assess mesopic sensitivity.
Time frame: Baseline and Month 12
Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Dec 2028, 34 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Jul 2028 → Dec 2028 and completion Jul 2028 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Astellas Pharma Global Development, Inc. →